Article
CLR 131 Continues to Show Encouraging Responses in Triple Refractory Multiple Myeloma
Rating:
0.0
Views:
73
Likes:
1
Library:
1
CLR 131 induced a clinically meaningful objective response rate of 40% as treatment of patients with multiple myeloma who are triple class refractory in the phase 2 CLOVER-1 clinical trial.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value